Mild cognitive impairment

VUNO Secures FDA 510(k) Clearance for VUNO Med®-DeepBrain®

Retrieved on: 
Monday, October 23, 2023
Mild cognitive impairment, FDA, Dementia, MRI, Food, MCI, WMH, SCD, Conference, Software, White matter, Quality of life, AAIC, Hand, AI, Patient, Diagnosis, Atrophy, Food and Drug Administration Amendments Act of 2007, Medical device, Medical imaging, Alzheimer's disease

SEOUL, South Korea, Oct. 23, 2023 /PRNewswire/ -- VUNO Inc., South Korean medical AI company has received 510(k) clearance from the Food and Drug Administration (FDA) for its AI-powered brain quantification device, VUNO Med®-DeepBrain®.

Key Points: 
  • SEOUL, South Korea, Oct. 23, 2023 /PRNewswire/ -- VUNO Inc., South Korean medical AI company has received 510(k) clearance from the Food and Drug Administration (FDA) for its AI-powered brain quantification device, VUNO Med®-DeepBrain®.
  • VUNO Med®-DeepBrain® is intended to automate the current manual process of identifying, labeling, and quantifying segmentable brain structures from MRI images.
  • With the FDA clearance in hand, VUNO intends to bolster its sales and marketing efforts targeting US medical institutions.
  • VUNO has previously explored the potential for early diagnosis of Alzheimer's disease with information provided by VUNO Med®-DeepBrain® through clinical research.

Oscotec/ADEL Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease

Retrieved on: 
Thursday, September 14, 2023
Partnership, Lysine, Clinical trial, Mild cognitive impairment, Pharmacokinetics, Brain, Tauopathy, Aggregation, Journal, Patient, Immunoglobulin G, Journal of Clinical Investigation, AD, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Alzheimer's disease, Food, Safety, Pharmaceutical industry, Vaccine

PANGYO, South Korea, Sept. 14, 2023 /PRNewswire/ -- Oscotec Inc. and ADEL Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application of ADEL-Y01 for the treatment of Alzheimer's disease (AD).

Key Points: 
  • PANGYO, South Korea, Sept. 14, 2023 /PRNewswire/ -- Oscotec Inc. and ADEL Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application of ADEL-Y01 for the treatment of Alzheimer's disease (AD).
  • Oscotec and ADEL are jointly developing a novel disease-modifying immunotherapy agent (ADEL-Y01) targeting tau protein accumulation in the AD brain.
  • "The IND clearance by the FDA represents a major achievement for us, especially in light of our first candidate entering into clinical trials," said Seung-Yong Yoon, M.D., CEO of ADEL.
  • "We are enthusiastic about commencing the clinical trial, as it brings us closer to providing therapeutic solutions for the patients grappling with tauopathies including AD."

Landmark Study Investigating Novel Alzheimer’s Biomarkers Advances to Data Analysis Stage

Retrieved on: 
Wednesday, June 14, 2023
Database, University, Biogen, Fear, Mild cognitive impairment, Mad, PET, Research, Biomarker, MCI, GAP, Eli Lilly, Reno 1868 FC, Alzheimer's disease, Dementia, Patient, IRB, Collection, Risk, Gates Ventures, Diagnosis, Merck, FDA, African Americans, Disease, Medical imaging, Pharmaceutical industry, Medical device, AbbVie

The Bio-Hermes digital and blood-based biomarker study for Alzheimer’s disease will change how Alzheimer’s disease is assessed and how it is diagnosed and how people may learn about their risk for the disease.

Key Points: 
  • The Bio-Hermes digital and blood-based biomarker study for Alzheimer’s disease will change how Alzheimer’s disease is assessed and how it is diagnosed and how people may learn about their risk for the disease.
  • That’s why today, Global Alzheimer’s Platform Foundation® (GAP) President John Dwyer announced the next stage in its Bio-Hermes digital and blood-based biomarker study for Alzheimer’s disease.
  • The study closed in November 2022 with an unprecedented 24 percent level of participation from traditionally underrepresented communities.
  • “That’s why we won’t wait, and that drives the urgency behind our work on the Bio-Hermes study.

Neurowyzr and Allium Healthcare Announce a first-of-its-kind Partnership for Brain Health for Active Agers

Retrieved on: 
Wednesday, September 28, 2022
Venus, Neuroscience, Software, Diet, Risk, Brain, Nursing, World, LinkedIn, Population, Organization, Allium, Long-term care, Partnership, Stroke, Mild cognitive impairment, Intermediate, Active ageing, Cognitive deficit, CEO, Respite care, MCI, Solution, Dementia, Ageing, GLOBE, Health care, AI, Digital Solutions, Medical imaging

SINGAPORE, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Neurowyzr, the Singapore Deep Neuroscience and Brain Capital company with a vision to optimize population and corporate brain health and performance using neuroscience-based digital solutions, announces a partnership with Allium Healthcare to jointly develop brain health programs to help Active Agers screen, monitor, prevent and improve brain health.

Key Points: 
  • SINGAPORE, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Neurowyzr, the Singapore Deep Neuroscience and Brain Capital company with a vision to optimize population and corporate brain health and performance using neuroscience-based digital solutions, announces a partnership with Allium Healthcare to jointly develop brain health programs to help Active Agers screen, monitor, prevent and improve brain health.
  • Allium will be the first Intermediate and Long-Term care (ILTC) provider in Asia-Pacific to provide Active Ageing programs focused on the brain, using Neurowyzrs Digital Brain Function Screen and future brain health solutions.
  • Neurowyzr will also work with Allium to roll out future digital neuroscience solutions such as Digital Brain Health Diagnostics and Digital Therapy.
  • Bernie Poh, CEO, Allium Healthcare commented, Allium Healthcare works with leading and innovative teams to transform our vision for the finest of hospitality and healthcare into a reality.

Cerveau Technologies Inc. and Alnylam® Pharmaceuticals Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research

Retrieved on: 
Thursday, September 1, 2022
Technology, Biotechnology, Nanotechnology, Health, Neurology, Other Health, Radiology, Pharmaceutical, Other Technology, Research, General Health, Health Technology, Science, Clinical Trials, PET, Human, Technology, Alnylam Pharmaceuticals, Research, Neurodegeneration, Brain, Positron emission tomography, Rapunzel's Tangled Adventure (season 2), Mild cognitive impairment, Non-fungible token, Acceleration, Therapy, Patient, Medical imaging, Pharmaceutical industry

Cerveau Technologies, Inc. today announced a research collaboration agreement with Alnylam Pharmaceuticals (Alnylam), which will enable Alnylam to use Cerveaus [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain.

Key Points: 
  • Cerveau Technologies, Inc. today announced a research collaboration agreement with Alnylam Pharmaceuticals (Alnylam), which will enable Alnylam to use Cerveaus [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain.
  • NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimers disease.
  • The collaboration is focused on using [F-18]MK-6240 as a biomarker in Alnylams neurodegenerative disease drug research and development.
  • Cerveaus vision is globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimers disease.

DiamiR Biosciences Appoints Alidad Mireskandari, Ph.D., MBA, as Chief Executive Officer

Retrieved on: 
Monday, July 11, 2022
Mild cognitive impairment, Disease, Nomura Securities, News, Population, CEO, Industry, BNP Paribas, List of life sciences, Plasma, National, Pathology, Diamir, MicroRNA, National Cancer Institute, HIV disease progression rates, Alzheimer's disease, Research, Patient, Science, Foundation for the National Institutes of Health, MBA, Medical device, Medical imaging, HAVEN, Alidad

NEW HAVEN, Conn. and MONMOUTH JUNCTION, N.J., July 11, 2022 /PRNewswire/ -- DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced the appointment of Alidad Mireskandari, Ph.D., MBA as Chief Executive Officer (CEO), effective immediately.

Key Points: 
  • NEW HAVEN, Conn. and MONMOUTH JUNCTION, N.J., July 11, 2022 /PRNewswire/ -- DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced the appointment of Alidad Mireskandari, Ph.D., MBA as Chief Executive Officer (CEO), effective immediately.
  • Dr. Mireskandari most recently served as Chief Development Officer of Interpace Biosciences, and prior to that as President & CEO of JSGenetics.
  • From 2000 to 2009, Dr. Mireskandari was a hedge fund manager in charge of Life Sciences trading portfolios of Nomura Securities, BNP Paribas and Raeburn Advisors.
  • These statements are predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially.

Top 10 Warning Signs of Memory Loss & How to Seek Help According to Beverly Sanborn, Belmont Village Senior Living

Retrieved on: 
Wednesday, June 29, 2022
Seniors, Construction & Property, Nursing, Managed Care, Health, Mental Health, Consumer, Residential Building & Real Estate, People, Ageing, Diagnosis, San Francisco Bay Area, Lunch, Mild cognitive impairment, UCSD, Dementia, Program, Research, Socialization, Weight loss, Love, Depression, Brain, Delirium, Mood Swings, Friends, Drug, USC, Lists of diseases, Association, Personality, Vascular dementia, FORTUNE, Health, Risk, Partnership, Confusion, Amnesia, MCI, Cognitive reserve, Paranoia, Frontotemporal dementia, Medicine, Time, Family, Sanborn, Social isolation, Programming Development Manager, UCLA, Residential care, Mobile phone, Retail

Its normal to want to be optimistic and dismiss early signs and symptoms, but if memory lapses are consistent enough to cause concern, its best to be proactive and get help.

Key Points: 
  • Its normal to want to be optimistic and dismiss early signs and symptoms, but if memory lapses are consistent enough to cause concern, its best to be proactive and get help.
  • We often hear from family members that theyve seen signs of concern that arent readily apparent in routine phone calls or quick visits.
  • 10 Warning Signs of Memory Loss:
    Your loved one may struggle with recalling recent activities, information, conversations, and events.
  • Today, Belmont Village owns and operates 33 communities with just under 5,000 units, with an additional 1000 units in development.

KeifeRx to Present at BIO International Convention 2022

Retrieved on: 
Thursday, June 2, 2022
Lewy body dementias, MBBS, Lyme disease, Movement disorders, Amyotrophic lateral sclerosis, Patent, Georgetown University, Inflammation, BIO, Neurodegeneration, Solubility, Technology, Nilotinib, Alzheimer's disease, Mild cognitive impairment, TKI, Vaccine

Chris Hoyt, Chief Executive Office of KeifeRx, stated, "We are looking forward to presenting at the 2022 BIO International Convention and the opportunity to engage with potential investors and partners.

Key Points: 
  • Chris Hoyt, Chief Executive Office of KeifeRx, stated, "We are looking forward to presenting at the 2022 BIO International Convention and the opportunity to engage with potential investors and partners.
  • We're excited to collaborate at BIO and build long term relationships with partners who share our vision."
  • KeifeRx, is an emerging clinical-stage biopharmaceutical company developing novel and optimized, low dose, orally delivered tyrosine kinase inhibitors (TKIs) for the treatment of multiple neurodegenerative and immune diseases.
  • Additionally, KeifeRx is advancing its TKI formulations in neurodegenerative diseases, including Mild Cognitive Impairment, and movement disorders, including Lewy Body Dementia and Amyotrophic Lateral Sclerosis.

Study: More Positive Results for People with Pre-dementia Conditions

Retrieved on: 
Tuesday, April 12, 2022
CEO, Medicare, American Academy of Neurology, Amnesia, Â, Mild cognitive impairment, Science, Social cognition, Brain, Dementia, Stanford University, GLOBE, Patient, SAN, Decision-making, University, Even and odd functions, Neurology, Posit Science Corporation, Cognition, American Academy, MCI, FDA, Quality of life, Risk, Attention, Gait, Library, Memory, Mobile phone, Medical device

One prior study indicated that 65% of people with MCI progressed to dementia within three years .

Key Points: 
  • One prior study indicated that 65% of people with MCI progressed to dementia within three years .
  • Each group was asked to engage in their activity four times a week, for an hour a session, for six weeks.
  • These new results extend the idea that the brain can be rewired even in people at risk for dementia.
  • This is the twentieth study report indicating these exercises can drive improvements in brain health in people with pre-dementia conditions, Dr. Mahncke added.

Altoida upsizes its Series A Round to $20.3M to Advance Its First in Class AI-Powered Neurocognitive Assessment Platform

Retrieved on: 
Wednesday, March 30, 2022
Software, Research, General Health, Professional Services, Hardware, Pharmaceutical, Data Management, Mental Health, Technology, Science, Biotechnology, Finance, Health, Diamond, Drug development, Method, Alzheimer's disease, Biomarker, Cognition, Lists of diseases, Whitecaps, Merck Group, Investment, Neurology, MCI, Smartphone, Neurodegeneration, AR, Research, DC, AI, Standard of care, Dementia, Merck, CEO, Software, Gold, Health, Artificial intelligence, Technology, Twitter, Medtech, Machine learning, Science, Partner, Solution, FDA, Venture, Engineering, Augmented reality, Patient, Mild cognitive impairment, Pharmaceutical industry, Medical imaging, Medical device, Doctor of Philosophy, Schizophrenia, ALTOIDA, INC., M VENTURES, WHITECAP VENTURE PARTNERS

The investment was co-led by M Ventures (the corporate venture capital arm of Merck KGaA, Darmstadt, Germany) and Whitecap Venture Partners.

Key Points: 
  • The investment was co-led by M Ventures (the corporate venture capital arm of Merck KGaA, Darmstadt, Germany) and Whitecap Venture Partners.
  • Globally, Alzheimer's disease and related dementias (ADRD) affect 47 million people , with cases staggeringly expected to double in the next 20 years .
  • We are pleased to have new investors join Altoida and to have our existing investors continue their support.
  • Altoida is pioneering a new category of precision neurology, and were thrilled to co-lead this round, said Shayn Diamond, Partner at Whitecap Venture Partners.